Regeneron Pharmaceuticals Inc (REGN)

555.79 -11.25  -1.98% NASDAQ Oct 29, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/05/2020 08:30 EST Misc Regeneron Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Regeneron Pharmaceuticals Inc Third Quarter Earnings Result for 2020
08/05/2020 08:30 EDT Misc Regeneron Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020
08/05/2020 Earnings Regeneron Pharmaceuticals Inc Second Quarter Earnings Result for 2020
06/12/2020 10:30 EDT Misc Regeneron Pharmaceuticals Inc Annual General Meeting for 2019
05/05/2020 08:30 EDT Misc Regeneron Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Regeneron Pharmaceuticals Inc First Quarter Earnings Result for 2020
02/07/2020 Misc Regeneron Pharmaceuticals Inc Annual Report for 2019
02/06/2020 Earnings Regeneron Pharmaceuticals Inc Fourth Quarter Earnings for 2019 Release
02/06/2020 08:00 EST Misc Regeneron Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.regeneron.com
  • Investor Relations URL: http://newsroom.regeneron.com/
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Large Cap/Blend
  • Next Earnings Release: Nov. 05, 2020
  • Last Earnings Release: Aug. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 6.47%
HQH Tekla Healthcare Investors 6.17%
FBIOX Fidelity® Select Biotechnology 6.02%
VGHCX Vanguard Health Care Inv 3.36%
JLGQX JPMorgan Large Cap Growth R4 1.58%
XLV Health Care Select Sector SPDR® ETF 1.54%
ACWV iShares MSCI Global Min Vol Factor ETF 1.32%
USMV iShares MSCI USA Min Vol Factor ETF 1.32%
VHT Vanguard Health Care ETF 1.18%
CFNEX American Funds Fundamental Invs 529E 1.13%
FCNKX Fidelity® Contrafund® K 1.03%
RGEBX American Funds Growth Fund of Amer R2E 0.79%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.